RIP XTu­it: Great brains, hot tar­get and vet CEO Deb­o­rah Dun­sire in charge couldn’t stop this biotech from go­ing down

The biotech news these days is dom­i­nat­ed by star­tups and big mon­ey, but the cau­tion­ary tales still keep com­ing. 

XTu­it Phar­ma­ceu­ti­cals had banked on the ideas of some of the most promi­nent sci­en­tists en­gaged in drug de­vel­op­ment, re­lied on a sea­soned biotech ex­ec as CEO and had sol­id back­ing from some mar­quee in­vestors like Po­laris and NEA.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER